Literature DB >> 18996244

Performance-based or self-report measures of physical function: which should be used in clinical trials of hip fracture patients?

Nancy K Latham1, Vinay Mehta, Allison Martin Nguyen, Alan M Jette, Sippy Olarsch, Dimitris Papanicolaou, Julie Chandler.   

Abstract

OBJECTIVES: To assess the validity, sensitivity to change, and responsiveness of 3 self-report and 4 performance-based measures of physical function: activity measure for postacute care (AM-PAC) Physical Mobility and Personal Care scales, the Medical Outcomes Study 36-Item Short Form Health Survey Physical Function scale (SF-36 PF), the Physical Functional Performance test (PFP-10), the Short Physical Performance Battery (SPPB), a 4-meter gait speed, and the six-minute walk test (6MWT).
DESIGN: A prospective observational study of patients after a hip fracture. Assessments were performed at baseline and 12 weeks postenrollment.
SETTING: Inpatient and outpatient rehabilitation facilities in Norway, the United Kingdom, Sweden, Israel, Germany, the United States, Denmark, and Spain. PARTICIPANTS: A sample of study participants (N=108) who had a hip fracture.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Assessments of validity (known-groups, concurrent, construct, and predictive), sensitivity to change (effect size, standardized response mean [SRM], SE of measure, minimal detectable change (MDC), and responsiveness (optimal operating cut-points and area under the curve) between baseline and 12-week follow-up.
RESULTS: All physical function measures achieved comparably acceptable levels of validity. Odds ratios in predicting patient Global Assessment of Improvement at 12 weeks were as follows: AM-PAC Physical Mobility scale, 5.3; AM-PAC Personal Care scale, 3.6; SF-36 PF, 4.3; SPPB, 2.0; PFP-10, 2.5; gait speed, 1.9; and 6MWT, 2.4. Effect sizes and SRM exceeded 1 SD for all 7 measures. Percent of patients who exceeded the MDC(90) at week 12 were as follows: AM-PAC Physical Mobility scale, 90%; AM-PAC Personal Care scale, 74%; SF-36 PF, 66%; SPPB, 36%; PFP-10, 75%; gait speed, 69%; and 6MWT, 75%. When evaluating responsiveness using the area under receiver operating curves for each measure, all measures had acceptable responsiveness, and no pattern emerged of superior responsiveness depending on the type of measure used.
CONCLUSIONS: Findings reveal that the validity, sensitivity, and responsiveness of self-report measures of physical function are comparable to performance-based measures in a sample of patients followed after fracturing a hip. From a psychometric perspective, either type of functional measure would be suitable for use in clinical trials where improvement in function is an endpoint of interest. The selection of the most appropriate type of functional measure as the primary endpoint for a clinical trial will depend on other factors, such as the measure's feasibility or the strength of the association between the hypothesized mechanism of action of the study intervention and a functional outcome measure.

Entities:  

Mesh:

Year:  2008        PMID: 18996244     DOI: 10.1016/j.apmr.2008.04.016

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  52 in total

1.  The PROMIS initiative: involvement of rehabilitation stakeholders in development and examples of applications in rehabilitation research.

Authors:  Dagmar Amtmann; Karon F Cook; Kurt L Johnson; David Cella
Journal:  Arch Phys Med Rehabil       Date:  2011-10       Impact factor: 3.966

2.  Responsiveness and validity of the six-minute walk test in individuals with traumatic brain injury.

Authors:  Kurt A Mossberg; Elizabeth Fortini
Journal:  Phys Ther       Date:  2012-01-26

3.  Geriatric rehabilitation after hip fracture. Role of body-fixed sensor measurements of physical activity.

Authors:  P Benzinger; U Lindemann; C Becker; K Aminian; M Jamour; S E Flick
Journal:  Z Gerontol Geriatr       Date:  2014-04       Impact factor: 1.281

4.  Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL): Effects on Bone Structure and Architecture.

Authors:  Catherine M Donlon; Meryl S LeBoff; Sharon H Chou; Nancy R Cook; Trisha Copeland; Julie E Buring; Vadim Bubes; Gregory Kotler; JoAnn E Manson
Journal:  Contemp Clin Trials       Date:  2018-02-23       Impact factor: 2.226

5.  Timeline of functional recovery after hip fracture in seniors aged 65 and older: a prospective observational analysis.

Authors:  K Fischer; M Trombik; G Freystätter; A Egli; R Theiler; H A Bischoff-Ferrari
Journal:  Osteoporos Int       Date:  2019-04-02       Impact factor: 4.507

6.  What physical attributes underlie self-reported vs. observed ability to walk 400 m in later life? An analysis from the InCHIANTI Study.

Authors:  Marla K Beauchamp; Suzanne G Leveille; Kushang V Patel; Dan K Kiely; Caroline L Phillips; Stefania Bandinelli; Luigi Ferrucci; Jack Guralnik; Jonathan F Bean
Journal:  Am J Phys Med Rehabil       Date:  2014-05       Impact factor: 2.159

7.  Potential Functional Benefit From Light Intensity Physical Activity in Knee Osteoarthritis.

Authors:  Daniel K White; Jungwha Lee; Jing Song; Rowland W Chang; Dorothy Dunlop
Journal:  Am J Prev Med       Date:  2017-08-30       Impact factor: 5.043

8.  DESIGNING DRUG TRIALS FOR SARCOPENIA IN OLDER ADULTS WITH HIP FRACTURE - A TASK FORCE FROM THE INTERNATIONAL CONFERENCE ONFRAILTY AND SARCOPENIA RESEARCH (ICFSR).

Authors:  B Vellas; R Fielding; R Miller; Y Rolland; S Bhasin; J Magaziner; H Bischoff-Ferrari
Journal:  J Frailty Aging       Date:  2014

9.  Nested Cohort Study to Identify Characteristics That Predict Near-Term Disablement From Lung Cancer Brain Metastases.

Authors:  Andrea L Cheville; Jeffrey R Basford; Ian Parney; Ping Yang; Felix E Diehn
Journal:  Arch Phys Med Rehabil       Date:  2016-09-22       Impact factor: 3.966

10.  Effect of a home-based exercise program on functional recovery following rehabilitation after hip fracture: a randomized clinical trial.

Authors:  Nancy K Latham; Bette Ann Harris; Jonathan F Bean; Timothy Heeren; Christine Goodyear; Stacey Zawacki; Diane M Heislein; Jabed Mustafa; Poonam Pardasaney; Marie Giorgetti; Nicole Holt; Lori Goehring; Alan M Jette
Journal:  JAMA       Date:  2014-02-19       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.